Equity Events is a Brisbane based company which specialises in organising investment events for the mining, energy, exploration and industrial sectors. Each year the host the very successful Noosa Mining Conference.
Copyright 2024 – Finance News Network
09 March 2023 - Knosys Limited (ASX:KNO) Managing Director John Thompson discusses drivers of revenue growth, the roadmap for the company's three SaaS solutions, onshoring GreenOrbit operations and outlook for the second half.
31 Aug 2022 - LBT Innovations Limited (ASX:LBT) CEO and Managing Director Brent Barnes discusses new opportunities for the company's automation technology.
20 Jul 2020 - BluGlass Limited (ASX:BLG) Managing Director and CEO Giles Bourne gives an update on the commissioning of the BLG 500 at Silverwater, strategic alliances and product roadmap.
28 Nov 2022 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses the LAG-3 landscape, the company's portfolio of therapies, encouraging data from the 2022 SITC conference and the outlook for 2023.
26 Sep 2019 - First Graphene Limited (ASX:FGR) Executive Director and CFO, Peter Young talks about the company's worldwide licensing agreement with the University of Manchester for its technology used in supercapacitors.
28 Feb 2020 - Washington H. Soul Pattinson and Company Limited (ASX:SOL) Managing Director, Todd Barlow provides a portfolio update and talks about the approach to investment that has enabled the company to outperform over decades.
12 Aug 2021 - eCargo Holdings Limited (ASX:ECG) Group CEO Lawrence Lun provides an introduction to the company's platform, partners and retail brands, discussing how it grows sales in China through a combination of data and technology.
23 Oct 2019 - Cashwerkz Limited (ASX:CWZ) Executive Director, Craig Swanger talks about the company's platform, the benefit it provides for both banks and investors, FY19 results and outlook.
26 Aug 2021 - Chimeric Therapeutics Limited (ASX:CHM) Chief Operating Officer Jennifer Chow talks about the company's licensing of a novel, third-generation CDH17 CAR T cell therapy from the University of Pennsylvania, its recent FDA IND clearance and plans for ongoing growth.